Tom Steyer has Crinetics Pharmaceuticals, ticker CRNX, on his radar and recent filings show heavy institutional interest; the company’s big bet is PALSONIFY, an oral therapy that just cleared key regulatory hurdles and could upend how acromegaly is treated. This piece walks through the ownership moves, the approval momentum, early adoption signals and the realistic risks that come with any emerging biotech story. Read on for a clear, no-fluff look at why CRNX made the cut on that list and what to watch next.
Crinetics landed at number six on the list titled “Billionaire Tom Steyer’s 10 Stock Picks with Huge Upside Potential,” a spot that immediately draws attention from both retail and institutional investors. When a high-profile investor highlights a name, it often sparks fresh scrutiny and forces a closer look at fundamentals and catalysts. In CRNX’s case the catalyst is obvious: a newly approved oral drug and the market dynamics around it.
Institutional ownership of CRNX has been a bit of a roller coaster over the years. Farallon Capital first showed up in the company’s filings back in the third quarter of 2018 with a notable stake, which was later sold off in early 2019, then resurfaced in 2023 and swung again. The most recent disclosures show a meaningful ramp in holdings, with reported shares rising to just under seven million by the fourth quarter of 2025, roughly 20 percent higher than the prior quarter.
The commercial story centers on PALSONIFY, billed as the first once-daily oral option for acromegaly, and that’s a big deal in a field dominated by injections. The drug has cleared both the US Food and Drug Administration and the European Commission, giving Crinetics a global runway to push adoption. For patients the convenience tradeoff is obvious, and for prescribers it’s the first oral lever they can pull for a condition that’s long required monthly injections.
Early uptake metrics are modest but meaningful: initial data points suggest about a five percent adoption rate within months of launch, which has hedge funds and analysts recalibrating forecasts. Some researchers now peg 2026 revenue estimates near $62 million, a number that outpaces earlier consensus. Those figures are the kind of proof points that can convince larger payers and specialty pharmacies to broaden access faster than expected.
That said, the road from approval to blockbuster is rarely straight. Acromegaly is a niche market and payer dynamics, pricing negotiations and real-world effectiveness will dictate how quickly oral therapy displaces injected standards. Competing treatments, provider habits and the need for long-term safety data all play into the uptake curve, so the early five percent metric is promising but far from a guarantee of runaway success.
Investors should also remember typical biotech volatility: clinical setbacks, supply chain hiccups, or unexpected payer restrictions can knock a stock around quickly. Institutional buying can amplify moves in both directions, especially when a name gains the attention of macro-focused billionaires and hedge funds. That makes position sizing and timeline expectations key for anyone considering exposure.
Where CRNX shines is a clear product differentiation and regulatory green lights in major markets, which together create a tangible commercial opportunity. Monitoring first-quarter launch numbers, formulary placements and real-world adherence data will tell the story faster than press releases. If PALSONIFY proves easier to use and achieves steady reimbursement, the adoption curve could steepen beyond those early projections.
For watchful investors, a few concrete signals matter: sustained quarter-over-quarter prescription growth, expanding payer coverage, and any early safety or efficacy notes from real-world use. Keep an eye on institutional 13F filings and insider moves too, since the pattern of accumulation from funds can signal conviction or repositioning. Those data points will separate short-lived hype from a durable commercial story.
Bottom line: Crinetics is squarely in the spotlight because it offers something patients and prescribers want—an oral alternative to injections—and it has regulatory approval to sell it. That combination explains why the stock landed on the high-profile list and why institutional wallets have shifted in and out before ultimately growing larger. The next chapters will be written in launch metrics, payer decisions and how fast the market accepts a once-daily pill over a monthly shot.
